AstraZeneca: Tozorakimab Demonstrated Statistically Significant and Highly Clinically Meaningful Reduction in COPD Exacerbations in OBERON and TITANIA Phase III Trials
September 09, 2026
September 09, 2026
WILMINGTON, Delaware, Sept. 9 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds
Full results published in the New England Journal of Medicine and presented at the . . .
* * *
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds
Full results published in the New England Journal of Medicine and presented at the . . .